



APR 8 1992

Re: Dermatop®  
Docket No. 91E-0476

Food and Drug Administration  
Rockville MD 20857

#14

The Honorable Harry F. Manbeck, Jr.  
Assistant Secretary of Commerce  
and Commissioner of Patents and Trademarks  
Washington, D.C. 20231

Dear Commissioner Manbeck:

This is in regard to the application for patent term extension for U.S. Patent No. 4,242,334, filed by Hoechst Aktiengesellschaft, under 35 U.S.C. 156 et seq. We have reviewed the dates contained in the application and have determined the regulatory review period for Dermatop, the human drug product claimed by the patent.

The total length of the review period for Dermatop® is 3,532 days. Of this time, 1,450 days occurred during the testing phase and 2,082 days occurred during the approval phase. These periods of time were derived from the following dates:

1. The date an exemption under subsection 505(i) of the Federal Food, Drug, and Cosmetic Act involving this drug product became effective: January 21, 1982.

The applicant claims January 22, 1982, as the date the investigational new drug application (IND) became effective. However, FDA records indicate that the IND effective date was January 21, 1982, which was thirty days after FDA receipt of the IND.

2. The date the application was initially submitted with respect to the human drug product under subsection 505(b) of the Federal Food, Drug, and Cosmetic Act: January 10, 1986.

FDA has verified the applicant's claim that NDA 19-568 was submitted on January 10, 1986.


3. The date the application was approved: September 23, 1991.

FDA has verified the applicant's claim that NDA 19-568 was approved on September 23, 1991.

This determination of the regulatory review period by FDA does not take into account the effective date of the patent, nor does it exclude one-half of the testing phase as required by 35 U.S.C. 156(c)(2).

Please let me know if we can be of further assistance.

Sincerely yours,

A handwritten signature in dark ink, appearing to read "Stuart L. Nightingale". The signature is fluid and cursive, with the first name "Stuart" being the most prominent.

Stuart L. Nightingale, M.D.  
Associate Commissioner  
for Health Affairs

cc: Tatsuya Ikeda  
Hoechst Celanese Corp., Patent Dept.  
Route 202-206  
P.O. Box 2500  
Somerville, NJ 08876-1258